Peter Kaiser, Ph.D.

Home
Research & Reports
About Our Research
Previously Funded Researchers
Peter Kaiser, Ph.D.

Research Project:
Drugs to Reactivate Tumor-Killing Ability of p53

Research Topics:

gene expression transcription
gene therapy

Research Disease:

lung cancer

One of the most commonly mutated genes in cancer and one of the most difficult proteins to target therapeutically is p53. The malfunction of p53 is crucial for the origin and spread of lung cancer. We aim develop new cancer drugs targeting p53 to help patients suffering from this terrible disease. Drugs able to reactivate the tumor-killing ability of p53 will be a significant new treatment option for thousands of lung cancer patients and will also improve treatment options for patients fighting other types of cancers.

Page last updated: June 7, 2024

Peter Kaiser, Ph.D.

A Breath of Fresh Air in Your Inbox

Select Your Location

Change Language

Lung HelpLine

1-800-LUNG-USA